About Tony Weiss
Professor Anthony (Tony) Weiss AM PhD FAA FTSE FAHMS FRSN FRACI FRSC FRSB FAIMBE FNAI FBSE FTERM is the McCaughey Chair in Biochemistry, NHMRC Leadership Fellow (Level 3), and Professor of Biochemistry & Molecular Biotechnology, and leads Tissue Engineering & Regenerative Medicine in the Charles Perkins Centre at the University of Sydney.
He is the leading researcher on human tropoelastin, which gives tissue its elasticity, promotes healing, and enhances the repair of scars and wounds.
He is on 14 Editorial Boards and inventor on 174 granted international patents in 23 patent families.
He is one of the most highly awarded innovators in Australia: The Order of Australia, Prime Minister’s Prize for Innovation, Premier’s Prize for Science & Engineering Leadership in Innovation, Eureka Prize for Innovation in Medical Research, Australian Academy of Technology & Engineering’s Clunies Ross Award, Australian Academy of Science’s Ian Wark Medal, ASBMB Lemberg Medal, Vice Chancellor’s Award for Excellence, Australasian Society for Biomaterials & Tissue Engineering’s Award for Research Excellence, Innovator of Influence Award, Roslyn Flora Goulston Prize, David Syme Research Medal, ASBMB Pharmacia Biotechnology Medal, NSW Commercialisation Expo Prize, Australian Innovation Challenge Award, MBSANZ Barry Preston Award, FAOBMB Entrepreneurship Award, RACI Applied Research Medal, RACI Weickhardt Medal, NIH Fogarty International Fellow, and Fulbright Scholar.
He is Chair of the Fellows of Tissue Engineering & Regenerative Medicine and Immediate Past President of the Tissue Engineering & Regenerative Medicine International Society (TERMIS), was elected Chair of TERMIS Asia Pacific, and President of MBSANZ, and is a Fellow of the Australian Academy of Science, Australian Academy of Technology and Engineering, Australian Academy of Health and Medical Sciences, Royal Society of NSW, Royal Society of Chemistry, Royal Australian Chemical Institute,US National Academy of Inventors, American Institute for Medical and Biological Engineering, Tissue Engineering and Regenerative Medicine, and Biomaterials Science and Engineering.
He founded the clinical stage company Elastagen Pty Ltd which was spun off from the University of Sydney to commercialise tropoelastin. Benefitting from a remarkable executive and board, Elastagen was acquired by Allergan, an AbbVie company, in one of the largest transactions completed in the Australian life science sector.Type your paragraph here.